Is Enclomiphene Actually Dangerous?

Enclomiphene keeps getting lumped in with clomiphene, and that confusion is costing people accurate information about what the compound actually does and what risks it actually carries.

To understand why the distinction matters, you need to understand how both drugs work inside the same biological system.

Your brain runs testosterone production through a feedback loop that operates like a thermostat. The hypothalamus releases something called GnRH, which is a signaling hormone that tells your pituitary to release LH and FSH, and those signals travel to the testes and trigger testosterone production. When testosterone rises, the brain senses it, converts some of it to estradiol, and uses that estradiol to turn the signal back down. The system is always listening for estradiol levels as its primary off-switch.

Clomiphene works by blocking estrogen receptors in the hypothalamus and pituitary, which means the brain cannot sense estradiol properly, so it assumes levels are low and keeps the signal running higher, which pushes LH and FSH up, which drives more testosterone production from the testes. That is the whole mechanism. And enclomiphene does exactly that.

The problem is that clomiphene is not a single compound. It is a mixture of two molecules called isomers, which means they share the same chemical formula but fold into different shapes and behave completely differently in the body. Clomiphene is roughly 62 percent enclomiphene and 38 percent of a second isomer called zuclomiphene, and those two molecules do opposite things.

Enclomiphene blocks estrogen receptors. Zuclomiphene activates them.

So when a man takes clomiphene, he is simultaneously receiving a compound that suppresses the estrogen signal at the brain and a compound that mimics estrogen in other tissues, and those effects pull in opposing directions at the same time.

There is also a timing problem. Enclomiphene clears the body in roughly 10 hours. Zuclomiphene accumulates and lingers for days. So even after the enclomiphene is gone, the zuclomiphene is still occupying estrogen receptors throughout the body, activating them, and driving effects that are genuinely estrogenic in tissues outside the brain.

This is why the side effect profiles of the two compounds look so different when measured head to head.

A 2024 study from Baylor enrolled 66 men and put both compounds through a direct comparison. On clomiphene, 47 percent of men reported side effects. On enclomiphene, that number was 13.8 percent, and that difference was statistically significant at p equals 0.001. Mood changes occurred in 9.1 percent of clomiphene users and zero percent of enclomiphene users. Decreased libido dropped from 33.3 percent on clomiphene down to 8.6 percent on enclomiphene.

The estradiol data from that same study tells you exactly why. Clomiphene raised estradiol. Enclomiphene decreased it. That single difference in what happens to estradiol levels downstream explains most of the symptom gap between the two drugs.

When you look at a broader picture, a 2025 meta-analysis pulled together 10 randomized controlled trials covering 819 patients and found that across all of the published data, no severe adverse events were recorded in any study. SERM therapy, which is the drug class both compounds belong to, raised total testosterone by an average of 273.76 ng/dL compared to placebo.

Earlier work from 2013 tracked 44 men on enclomiphene for six weeks and found that a 25 mg dose brought average testosterone to 604 ng/dL, with no changes to thyroid stimulating hormone, cortisol, ACTH, lipids, or bone markers. A 2014 study followed 124 men for three months on a lower 12.5 mg dose and saw testosterone rise from 217 to 472 ng/dL while mean sperm counts held at 176 million per milliliter, which is the opposite of what testosterone replacement therapy does to sperm production.

That last point is not a minor detail. TRT suppresses the LH and FSH signal completely, which collapses sperm production. Enclomiphene works upstream, amplifying the natural signal, so the testes stay active throughout treatment. For men who care about preserving fertility, this is the mechanistic reason enclomiphene gets used instead of exogenous testosterone.

Now the honest limits of the data. The longest published follow-up in the literature is around six months, so there is no long-term safety record beyond that window. Anything past six months is extrapolation, not data. The FDA rejected the branded formulation of enclomiphene, called Androxal, but the rejection was tied to study design concerns, not to safety findings. The compound is currently available primarily through compounding pharmacies, and because compounding quality is not standardized the way pharmaceutical manufacturing is, product purity can vary in ways that the clinical trials cannot account for.

So the picture that actually emerges from the data is this. The side effects most people associate with clomiphene, the mood disruption, the libido suppression, the elevated estrogen, those trace primarily to zuclomiphene, not to enclomiphene. Separating the two isomers separates most of those risks. What remains is a compound with a 13.8 percent reported side effect rate across published trials, no recorded severe adverse events in a meta-analysis of nearly 800 patients, and no known mechanism through which it would cause the kinds of harm people are currently attributing to it on social media.

The fear of enclomiphene is mostly borrowed from clomiphene, and treating them as the same drug is the same mistake as blaming a car accident on both front seat passengers because they rode in the same vehicle.

---

References

1. Saffati G, Kassab J, Orozco Rendon D, et al. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men. Translational Andrology and Urology. 2024;139:1979-1987. Finding: Side effects: clomiphene 47% vs enclomiphene 13.8% p=0.001. Mood changes: 9.1% vs 0% p=0.03. Decreased libido: 33.3% vs 8.6% p=0.001. Estradiol decreased with enclomiphene, increased with clomiphene p=0.001. Source
2. Hohl A, Chavez MP, Pasqualotto E, et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Archives of Endocrinology and Metabolism. 2025. Finding: 10 RCTs, 819 patients. SERM therapy increased total testosterone by 273.76 ng/dL vs placebo p<0.01. 21% experienced adverse events; none were severe. Source
3. Wiehle RD, Cunningham GR, Pitteloud N, et al. Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism. BJU International. 2013;1128:1188-1200. Finding: 44 men, 6 weeks. 25 mg enclomiphene averaged 604 ng/dL testosterone. No effects on TSH, ACTH, cortisol, lipids, or bone markers. Source
4. Wiehle R, Fontenot GK, Wike J, et al. Enclomiphene citrate stimulates testosterone production while preventing oligospermia. Fertility and Sterility. 2014;1023:720-727. Finding: 124 men, 3 months. Testosterone rose from 217 to 472 ng/dL 12.5 mg. Sperm counts preserved mean 176 million/mL. Source

---

Join the free community:
Men: Iron Forge Brotherhood
Women: Powerhouse Fitness